TW201609752A - 抗病毒化合物之晶形 - Google Patents

抗病毒化合物之晶形 Download PDF

Info

Publication number
TW201609752A
TW201609752A TW103144805A TW103144805A TW201609752A TW 201609752 A TW201609752 A TW 201609752A TW 103144805 A TW103144805 A TW 103144805A TW 103144805 A TW103144805 A TW 103144805A TW 201609752 A TW201609752 A TW 201609752A
Authority
TW
Taiwan
Prior art keywords
compound
diffraction pattern
crystal form
ray powder
curve
Prior art date
Application number
TW103144805A
Other languages
English (en)
Chinese (zh)
Inventor
達斯汀 布琳莉
祖漢 陳
智超 馮
凱帝 奇頓
歐佳 拉彼那
亨利 莫里森
多尼明加 派尙
Original Assignee
吉李德科學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 吉李德科學股份有限公司 filed Critical 吉李德科學股份有限公司
Publication of TW201609752A publication Critical patent/TW201609752A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
TW103144805A 2013-12-23 2014-12-22 抗病毒化合物之晶形 TW201609752A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361920427P 2013-12-23 2013-12-23

Publications (1)

Publication Number Publication Date
TW201609752A true TW201609752A (zh) 2016-03-16

Family

ID=52282995

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103144805A TW201609752A (zh) 2013-12-23 2014-12-22 抗病毒化合物之晶形

Country Status (12)

Country Link
US (2) US9562058B2 (OSRAM)
EP (1) EP3087086B1 (OSRAM)
JP (2) JP6568541B2 (OSRAM)
AR (1) AR098958A1 (OSRAM)
AU (1) AU2014370124A1 (OSRAM)
CA (1) CA2934049A1 (OSRAM)
ES (1) ES2708993T3 (OSRAM)
NZ (1) NZ720887A (OSRAM)
PT (1) PT3087086T (OSRAM)
TW (1) TW201609752A (OSRAM)
UY (1) UY35918A (OSRAM)
WO (1) WO2015100144A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ720745A (en) * 2013-12-23 2018-02-23 Gilead Sciences Inc Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN115417803B (zh) * 2022-08-30 2023-10-03 四川同晟生物医药有限公司 乌帕替尼中间体(3r,4s)-1-苄氧羰基-4-乙基吡咯烷-3-羧酸的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CL2008003384A1 (es) * 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
KR101313675B1 (ko) * 2008-07-22 2013-10-02 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티 에스.알.엘. Hcv ns3 프로테아제 억제제로서의 마크로사이클릭 퀴녹살린 화합물
WO2012040040A1 (en) * 2010-09-21 2012-03-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
KR101894704B1 (ko) * 2010-09-21 2018-09-05 이난타 파마슈티칼스, 인코포레이티드 매크로사이클릭 프롤린 유도된 hcv 세린 프로테아제 억제제
PT3431477T (pt) 2011-11-16 2020-12-15 Gilead Pharmasset Llc Imidazolilimidazolos condensados como compostos antivirais
UA119315C2 (uk) * 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с

Also Published As

Publication number Publication date
ES2708993T3 (es) 2019-04-12
JP6568541B2 (ja) 2019-08-28
US9862728B2 (en) 2018-01-09
NZ720887A (en) 2018-01-26
EP3087086B1 (en) 2018-11-07
US9562058B2 (en) 2017-02-07
WO2015100144A1 (en) 2015-07-02
CA2934049A1 (en) 2015-07-02
JP2019089819A (ja) 2019-06-13
UY35918A (es) 2015-05-29
PT3087086T (pt) 2019-02-06
AU2014370124A1 (en) 2016-06-23
EP3087086A1 (en) 2016-11-02
US20150175625A1 (en) 2015-06-25
JP2017503016A (ja) 2017-01-26
US20170267694A1 (en) 2017-09-21
AR098958A1 (es) 2016-06-22

Similar Documents

Publication Publication Date Title
TWI520966B (zh) 黃病毒科(Flaviviridae)病毒之巨環狀抑制劑
EP3492464B1 (en) Intermediates for preparing inhibitors of hepatitis c virus
CA3095528C (en) Antiviral compounds
JP6033362B2 (ja) 抗ウイルス治療のための2′−フルオロ置換カルバ−ヌクレオシド類似体
US8476225B2 (en) Antiviral compounds
TWI491609B (zh) 黃熱病毒科(Flaviviridae)病毒之抑制劑類
US20120053148A1 (en) Inhibitors of hepatitis c virus
TWI448457B (zh) 治療劑的藥物動力學性質之調節劑
JP7151956B2 (ja) ヌクレオシドホスフェート化合物並びに当該ヌクレオシドホスフェート化合物の調製方法及び使用
JP2017503015A (ja) 抗ウイルス性ソホスブビル類似体の結晶形
JP2019089819A (ja) 大環状hcv ns3阻害トリペプチドの結晶形態
WO2013090840A1 (en) 2 -amino- pyrido [3, 2 -d] pyrimidine derivatives as hcv inhibitors
WO2013090929A1 (en) Amino quinoline derivatives inhibitors of hcv
TW201313697A (zh) 製備噻吩化合物之方法
Bjornson et al. Inhibitors of Hepatitis C virus
HK40009144B (en) Intermediates for preparing inhibitors of hepatitis c virus
HK40009144A (en) Intermediates for preparing inhibitors of hepatitis c virus
HK1191000B (en) Macrocyclic inhibitors of flaviviridae viruses
OA16370A (en) Mass transfert column.
OA16229A (en) 2'-Fluoro substituted carba-nucleoside analogs for antiviral treatment.